Earnings summaries and quarterly performance for APTARGROUP.
Executive leadership at APTARGROUP.
Stephan B. Tanda
Detailed
President and Chief Executive Officer
CEO
GT
Gael Touya
Detailed
President of Aptar Pharma
HT
Hedi Tlili
Detailed
President of Aptar Closures
KY
Kimberly Y. Chainey
Detailed
Executive Vice President, Chief Legal Officer and Secretary
MP
Marc Prieur
Detailed
President of Aptar Beauty
VK
Vanessa Kanu
Detailed
Executive Vice President and Chief Financial Officer
XG
Xiangwei Gong
Detailed
Executive Vice President, Strategic Group Development and President of Aptar Asia
Board of directors at APTARGROUP.
BC
B. Craig Owens
Detailed
Director
CM
Candace Matthews
Detailed
Chair of the Board
GL
George L. Fotiades
Detailed
Director
GK
Giovanna Kampouri Monnas
Detailed
Director
IM
Isabel Marey-Semper
Detailed
Director
JX
Julie Xing
Detailed
Director
MT
Matt Trerotola
Detailed
Director
RK
Ralf K. Wunderlich
Detailed
Director
SG
Sarah Glickman
Detailed
Director
Research analysts who have asked questions during APTARGROUP earnings calls.
DR
Daniel Rizzo
Jefferies
6 questions for ATR
Also covers: APD, ASH, AZZ +16 more
Gabe Hajde
Wells Fargo & Company
6 questions for ATR
Also covers: AMBP, AMCR, BALL +12 more
GS
George Staphos
Bank of America
6 questions for ATR
Also covers: AMBP, AMCR, AVY +18 more
Ghansham Panjabi
Robert W. Baird & Co.
6 questions for ATR
Also covers: AMCR, AVNT, AVY +20 more
Matthew Roberts
Raymond James
5 questions for ATR
Also covers: AMCR, AVY, GEF +4 more
ML
Matthew Larew
William Blair & Company
3 questions for ATR
Also covers: AMED, DNA, MASS +10 more
ML
Matt Larew
William Blair & Co.
2 questions for ATR
Also covers: AMED, AVTR, MASS +11 more
Paul Knight
KeyBanc Capital Markets
2 questions for ATR
Also covers: A, AVTR, AZTA +16 more
Recent press releases and 8-K filings for ATR.
AptarGroup Discusses 2025 Performance and Future Growth Drivers
ATR
New Projects/Investments
Guidance Update
Dividends
- AptarGroup generated $3.8 billion in annual revenue for 2025, with the Pharma segment contributing 46% of revenues and nearly 70% of Adjusted EBITDA, making it the fastest-growing and most profitable segment.
- The company emphasizes its technology leadership with over 7,300 patents, of which more than 4,500 are in Pharma, supporting its core growth engine.
- Aptar targets a long-term total revenue growth of 4%-7%, with the Pharma segment historically achieving a 9% revenue CAGR over the last decade and expecting continued growth from areas like injectables (including GLP-1s) and systemic nasal drug delivery.
- Aptar has a strong balance sheet with leverage at 1.38x EBITDA as of year-end 2025 and has returned $1.2 billion to shareholders over the past five years, marking its 32nd consecutive year of increasing dividends.
Mar 3, 2026, 6:05 PM
AptarGroup Highlights 2025 Financials and Future Growth Drivers
ATR
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Aptar reported $3.8 billion in annual revenue for 2025, with Pharma being its fastest-growing and most profitable segment, accounting for 46% of revenues and nearly 70% of adjusted EBITDA.
- The company's Pharma segment demonstrated a 9% revenue CAGR over the last 10 years and is positioned for future growth with a 7% projected market CAGR for pharma packaging, driven by a diversified pipeline including injectables and systemic nasal drug delivery.
- Aptar maintains a strong financial position with 1.38x EBITDA leverage as of the end of 2025 and has returned approximately $1.2 billion to shareholders over the past five years through dividends and share buybacks.
- The company emphasizes innovation, holding over 7,300 patents (62% in Pharma), and expects continued growth and margin improvement across its Beauty and Closures segments in 2026.
Mar 3, 2026, 6:05 PM
AptarGroup Highlights Strong 2025 Performance and Future Growth Drivers
ATR
Revenue Acceleration/Inflection
Dividends
Share Buyback
- AptarGroup reported $3.8 billion in annual revenue for 2025, with its Pharma segment, the fastest-growing and most profitable, contributing 46% of revenues and nearly 70% of adjusted EBITDA.
- The company maintains a strong balance sheet with 1.38x EBITDA leverage as of end-2025 and has returned approximately $1.2 billion to shareholders over the last five years, including 32 consecutive years of increasing dividends.
- AptarGroup's Pharma segment, which generated $1.7 billion in 2025, achieved a 9% revenue CAGR over the last 10 years and expects continued growth from its pipeline, including injectables (with double-digit growth in Q4 2025 partly from GLP-1s) and systemic nasal drug delivery.
- The company targets a long-term total revenue growth of 4%-7%, supported by projected market growth rates of 7% CAGR for pharma packaging, 4% CAGR for beauty, and 2% CAGR for closures.
- AptarGroup anticipates continued growth and margin improvement in its Beauty and Closures segments for 2026, following 2025 performance where Beauty sales grew 7% and Closures saw 4% product volume growth.
Mar 3, 2026, 6:05 PM
AptarGroup Provides Q1 Guidance and Business Segment Updates
ATR
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- AptarGroup is comfortable with its Q1 guidance of $1.13 to $1.21 and expects a good quarter, despite a $65 million impact from emergency medicine destocking, which is anticipated mostly in the first half of the year. The company maintains its overall margin target of 21%-23% and a Pharma margin target of 32%-36%.
- The company's proprietary drug delivery system business is strong, with a pipeline that includes GLP-1, neurodegenerative, mental health, and cardiovascular indications. Consumer-facing businesses have shown improvement, with the closure business within its long-term target range and the beauty business resuming growth, despite some operational hiccups in Q4.
- AptarGroup expects continued growth in injectables, including GLP-1, and believes oral GLP-1 will expand the market rather than flatten injectables, driven by efficacy, market needs, and producer strategies. The company has invested $200 million in new injectable facilities, including a massive new building in Normandy, France, and anticipates margin expansion in this segment through efficiencies and mix enrichment.
- AptarGroup's multi-region supply chain and 30-year presence in China, with state-of-the-art assets, position it well globally, with China business profitability on par or slightly better than the global company.
Feb 25, 2026, 2:45 PM
AptarGroup Reaffirms Q1 Guidance and Discusses Business Segment Performance
ATR
Guidance Update
New Projects/Investments
Demand Weakening
- AptarGroup reaffirmed its first-quarter guidance of $1.13 to $1.21 per share, expecting a good quarter overall, with the exception of emergency medicine.
- The Pharma business is anticipated to perform well, with the $65 million impact from emergency medicine destocking mostly in the first half, while injectables, including GLP-1, are growing briskly, supported by a robust proprietary drug delivery pipeline. The company has made significant investments in injectable capacity and expects margin expansion in this segment.
- The Closures business has been reinvigorated and is performing well, while the Beauty business is progressing with renovation efforts despite some Q4 operational hiccups.
- AptarGroup maintains a strong position in China, with its operations being as profitable or more profitable than the global company, and does not foresee a significant increase in competition from Chinese producers in its main markets.
Feb 25, 2026, 2:45 PM
AptarGroup Maintains Q1 Guidance and Highlights Pharma Growth Drivers
ATR
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- AptarGroup is comfortable with its Q1 guidance of $1.13 to $1.21 and expects a good quarter, despite a $65 million impact from emergency medicine destocking primarily in the first half. The company anticipates being within its long-term margin range for the year.
- The Pharma business is expected to perform very well, driven by growth in consumer healthcare and brisk expansion in injectables, including GLP-1. The company's pipeline is rich with new indications, and oral GLP-1 formats are projected to expand the overall market rather than cannibalize injectable growth.
- The Closures business has returned to its long-term target margin range, and the Beauty business has resumed growth, with Q4 operational issues considered non-representative of its underlying trajectory.
- AptarGroup has completed a massive investment in a new injectable facility in Normandy, France, providing long-term capacity, and its profitable, 30-year presence in China supports both domestic market needs and global development.
Feb 25, 2026, 2:45 PM
AptarGroup Reports Q4 and Full-Year 2025 Results, Provides Q1 2026 Outlook
ATR
Earnings
Guidance Update
Share Buyback
- AptarGroup reported Q4 2025 core sales growth of 5% and a 14% increase in reported sales, contributing to full-year 2025 core sales growth of 2%.
- Q4 2025 adjusted EBITDA decreased 2% to $191 million, with adjusted EPS at $1.25, primarily due to product mix, higher production costs in beauty, and declining emergency medicine demand.
- The company expects Q1 2026 adjusted EPS to be between $1.13-$1.21 per share and anticipates a $65 million revenue headwind from emergency medicine in 2026, mainly in the first half.
- A new share repurchase authorization of up to $600 million was announced, following $365 million in share repurchases for the full year 2025.
- The Pharma segment saw 4% core sales growth in Q4 2025, with injectables increasing 24% and prescription sales (excluding emergency medicines) growing 10%.
Feb 6, 2026, 2:00 PM
AptarGroup Announces Q4 and Full-Year 2025 Results
ATR
Earnings
Guidance Update
Debt Issuance
- AptarGroup reported strong Q4 2025 sales growth of 14% to $963 million, with core sales up 5%, and full-year 2025 reported sales increasing 5% to $3.8 billion.
- Adjusted EPS for Q4 2025 was $1.25, down from $1.62 in the prior year, while full-year adjusted EPS was $5.74, a slight decline of 1%. Adjusted EBITDA margin for Q4 was 19.8%, impacted by product mix and higher production costs in beauty and closures.
- The Pharma segment's core sales grew 4% (or 10% excluding emergency medicine), driven by strong demand in systemic nasal drug delivery and 24% growth in injectables. Beauty core sales increased 10%, and Closures core sales increased 1%.
- For 2026, the company anticipates continued strong growth in Pharma (excluding emergency medicine), improving demand in Beauty, and steady performance in Closures, while expecting a $65 million year-over-year headwind from emergency medicine.
- AptarGroup returned $486 million to shareholders in 2025 through share repurchases and dividends and issued $600 million of 4.75% senior notes in Q4 2025.
Feb 6, 2026, 2:00 PM
AptarGroup Reports Strong Q4 and Full Year 2025 Results, Announces New Share Repurchase Authorization
ATR
Earnings
Share Buyback
Dividends
- AptarGroup reported strong Q4 2025 performance with 14% reported sales growth and 5% core sales growth, achieving $1.25 adjusted earnings per share. For the full year 2025, reported sales grew 5% and core sales grew 2%, with adjusted earnings per share of $5.74 and adjusted EBITDA reaching $815 million.
- The company returned $206 million to shareholders in Q4 2025 and $486 million for the full year 2025 through share repurchases and dividends. The Board also approved a new authorization for the repurchase of up to $600 million of common stock , marking the 32nd consecutive year of paying an annually increasing dividend.
- Free cash flow for FY 2025 was $303 million. The company provided an outlook for Q1 2026, projecting adjusted net income attributable to AptarGroup, Inc. per diluted share between $1.13 and $1.21.
Feb 6, 2026, 2:00 PM
AptarGroup Announces Q4 and Full-Year 2025 Results
ATR
Earnings
Guidance Update
Dividends
- AptarGroup reported Q4 2025 reported sales of $963 million, a 14% increase, and full-year 2025 reported sales of $3.8 billion, up 5%.
- Q4 2025 adjusted EBITDA margin was approximately 20% and adjusted EPS was $1.25, impacted by higher production costs in beauty enclosures and a decline in emergency medicine demand.
- All three segments delivered core sales growth in Q4 2025, with pharma core sales up 4% (10% excluding emergency medicine), beauty core sales up 10%, and closures core sales up 1%.
- The company returned $486 million to shareholders in 2025, marking its 32nd consecutive year of increasing dividends, and anticipates sequential quarterly improvements in beauty and closures margins through the first half of 2026, with a stronger second half for full-year margins.
Feb 6, 2026, 2:00 PM
Quarterly earnings call transcripts for APTARGROUP.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more